Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various clinical regimens of drug

Journal of Infectious Diseases

Volumn 173, Issue 4, 1996, Pages 987-992

  Cherrington, J M ^a   Miner, R ^b   Hitchcock, M J M ^b   Lalezari, J P ^b   Drew, W L ^b  

^a GILEAD SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS SHEDDING;

EID: 0029997824     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.4.987     Document Type: Article

References (15)

1. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonyl-methoxyalkyl derivatives of purines and pyrimidines. Antiviral Res 1987;8:261-72.
2. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2(phosphonyl-methoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995;171:788-96.
3. Kupperman B, Lalezari J, Stagg R, et al. A phase II/III randomized study of immediate versus deferred intravenous (IV) cidofovir (CDV, HPMPC) for AIDS patients with peripheral CMV retinitis (CMV-R). In: Program and abstracts of the International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics, Geneva, 1995.
4. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
5. Jacobsen MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant patients with AIDS. J Infect Dis 1991;163:1348-51.
6. Smith IL, Giles RE, Spector SA. Reduced cytomegalovirus (CMV) susceptibility to foscarnet is found in ganciclovir-resistant isolates and foscarnet resistance is conferred by mutations in the CMV polymerase [abstract H115]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
7. Stanat SC, Reardon JE, Erice A, Jordan M, Drew WL, Biron KK. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991;35:2191-7.
8. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in cytomegalovirus-infected cells. Nature 1992;358:162-4.
9. Lurain NS, Spafford LE, Thompson KD. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol 1994;68:4427-31.
10. Wolf DG, Smith IL, Lee DJ, Freeman WR, Flores-Aguilar M, Spector SA. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 1995;95:257-63.
11. Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992;66:7146-52.
12. Tatarowitz WA, Lurain NS, Thompson KD. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J Infect Dis 1992;166:904-7.
13. Sullivan V, Biron KK, Talarico CL, et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993;37:19-25.
14. Lurain NS, Penland LK, and Thompson KD. Ganciclovir-resistant DNA polymerase mutants isolated from an HCMV clinical specimen [abstract 211]. In: Program and abstracts of the 19th International Herpesvirus Workshop, Vancouver, Canada, 1994.
15. Drew WL, Miner R, Busch DF, et al. Prevalence of cytomegalovirus (CMV) resistance in patients receiving ganciclovir for serious CMV infection. J Infect Dis 1991;163:716-9.